Revisiting the Safety of Prostaglandin Analog Eyelash Growth Products.

IF 2.2 3区医学 Q2 DERMATOLOGY Dermatologic Surgery Pub Date : 2021-05-01 DOI:10.1097/DSS.0000000000002928

Kenneth D Steinsapir, Samantha M G Steinsapir

{"title":"Revisiting the Safety of Prostaglandin Analog Eyelash Growth Products.","authors":"Kenneth D Steinsapir, Samantha M G Steinsapir","doi":"10.1097/DSS.0000000000002928","DOIUrl":null,"url":null,"abstract":"Background: The FDA approved bimatoprost ophthalmic solution 0.03% for treatment of eyelash hypotrichosis in 2008. Consumer concern persists regarding potential side effects of this product.Objective: To identify gaps in the safety information associated with the use of prostaglandin eyelash growth products.Materials and methods: Literature searches were performed using PubMed, Embase, and Nexis Uni databases without restriction to publication date, language, or study setting.Results: The literature pertaining to bimatoprost for treatment of eyelash hypotrichosis is dominated by industry-sponsored clinical trials. Study design choices create gaps in our understanding of the clinical safety of these products.Conclusion: Because of study design choice, clinical trials of bimatoprost for eyelash growth may have systematically underreported the incidence of drug application discomfort and prostaglandin-associated periorbitopathy. The risk of increased iris pigmentation remains inadequately investigated. Consequently, there is an ongoing need to educate and monitor patients who choose to use these products.","PeriodicalId":11289,"journal":{"name":"Dermatologic Surgery","volume":" ","pages":"658-665"},"PeriodicalIF":2.2000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/DSS.0000000000002928","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Background: The FDA approved bimatoprost ophthalmic solution 0.03% for treatment of eyelash hypotrichosis in 2008. Consumer concern persists regarding potential side effects of this product.

Objective: To identify gaps in the safety information associated with the use of prostaglandin eyelash growth products.

Materials and methods: Literature searches were performed using PubMed, Embase, and Nexis Uni databases without restriction to publication date, language, or study setting.

Results: The literature pertaining to bimatoprost for treatment of eyelash hypotrichosis is dominated by industry-sponsored clinical trials. Study design choices create gaps in our understanding of the clinical safety of these products.

Conclusion: Because of study design choice, clinical trials of bimatoprost for eyelash growth may have systematically underreported the incidence of drug application discomfort and prostaglandin-associated periorbitopathy. The risk of increased iris pigmentation remains inadequately investigated. Consequently, there is an ongoing need to educate and monitor patients who choose to use these products.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

重新审视前列腺素模拟睫毛生长产品的安全性。

背景:2008年FDA批准了0.03%的比马前列素眼液用于治疗睫毛少毛症。消费者对该产品潜在副作用的担忧持续存在。目的:找出与前列腺素睫毛生长产品使用相关的安全信息的空白。材料和方法:使用PubMed、Embase和Nexis Uni数据库进行文献检索，不受出版日期、语言或研究环境的限制。结果:有关比马前列素治疗睫毛少毛症的文献主要是由行业资助的临床试验。研究设计的选择使我们对这些产品的临床安全性的理解出现空白。结论:由于研究设计的选择，比马前列素用于睫毛生长的临床试验可能系统性地低估了药物应用不适和前列腺素相关的眼周病的发生率。虹膜色素沉着增加的风险仍未得到充分的调查。因此，有必要对选择使用这些产品的患者进行教育和监测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Dermatologic Surgery 医学-皮肤病学

CiteScore

3.10

自引率

16.70%

发文量

547

期刊介绍： Exclusively devoted to dermatologic surgery, the Dermatologic Surgery journal publishes the most clinically comprehensive and up-to-date information in its field. This unique monthly journal provides today’s most expansive and in-depth coverage of cosmetic and reconstructive skin surgery and skin cancer through peer-reviewed original articles, extensive illustrations, case reports, ongoing features, literature reviews and correspondence. The journal provides information on the latest scientific information for all types of dermatologic surgery including: -Ambulatory phlebectomy- Blepharoplasty- Body contouring- Chemical peels- Cryosurgery- Curettage and desiccation- Dermabrasion- Excision and closure- Flap Surgery- Grafting- Hair restoration surgery- Injectable neuromodulators- Laser surgery- Liposuction- Microdermabrasion- Microlipoinjection- Micropigmentation- Mohs micrographic surgery- Nail surgery- Phlebology- Sclerotherapy- Skin cancer surgery- Skin resurfacing- Soft-tissue fillers. Dermatologists, dermatologic surgeons, plastic surgeons, oculoplastic surgeons and facial plastic surgeons consider this a must-read publication for anyone in the field.